Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Maria Vieito Villar"'
Autor:
Agostina Stradella, Francois Ghiringhelli, Ana Maia, Macarena Gonzalez, Cécile Gouttefangeas, Ulrich Herrlinger, David Reardon, Ahmed Idbaih, Patrick Wen, Ghazaleh Tabatabai, Wolfgang Wick, Mirjam Renovanz, Maria Vieito Villar, Christophe Bonny, Joao Gamelas Magalhaes, Hélène Toussaint, Jean-Michel Paillarse, Marta GilMartin, Iris Mildenberger, Michael C Burger, Alice Hervieu, Mehdi Touat, Antje Wick
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/b66bf531835946ef99e16b169d7cc47a
Autor:
Emiliano Calvo Aller, Glenn Hanna, Maria Vieito Villar, Caroline Even, Victor Moreno, Chul Kim, Shuchi Gulati, Daniel Morgensztern, Ana Acuna-Villaorduna, Philippe Cassier, Dennie Jones, Florilene Bouisset, Daniela Sahlender, Elisabeth Rouits, Dany Spaggiari, Lars Damstrup, Carlos-Alberto Gomez-Roca
Publikováno v:
Regular and Young Investigator Award Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2028b5fbd64c167f25d424f7354d7b84
https://doi.org/10.1136/jitc-2022-sitc2022.0589
https://doi.org/10.1136/jitc-2022-sitc2022.0589
Autor:
Jose Ramón Antunez Lopez, Nieves Martinez Lago, Ihab Abdulkader Nallib, Maria Elena Padin Iruegas, Rafael Varela Ponte, Maria Vieito Villar, Rafael López, Juan José Carrera Alvarez
Publikováno v:
ecancermedicalscience
Background HER2 status is a predictive biomarker of response to trastuzumab in advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. However, there is relatively little known about the role of HER2 in resected gastric or GEJ adenocarcin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1430621c0b24716661f0755e370af157
https://doi.org/10.3332/ecancer.2020.1020
https://doi.org/10.3332/ecancer.2020.1020
Autor:
Maria Vieito Villar, Courtney Henry, Sapna Yadavilli, Victor Moreno, Antoine Italiano, Omid Hamid, Marc S. Ballas, Marco Balas, Michael Chisamore, Frans L. Opdam, Michele Maio, Xiao Ji, Jeffrey S. Weber, Axel Hoos, David C. Turner, Jose Manuel Trigo, Catherine E. Ellis
Publikováno v:
Cancer Research. 81:CT033-CT033
Background: INDUCE-1 is a first-in-human trial investigating FE, an IgG4 ICOS agonist non-T-cell depleting mAb, in monotherapy (mono) and combo with PD-1 inhibitor PE. ICOS is highly expressed in melanoma, an immunotherapy responsive tumor, and is a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3d9b7c93a073d91a373e87c6b7de4a05
https://doi.org/10.1158/1538-7445.am2021-ct033
https://doi.org/10.1158/1538-7445.am2021-ct033
Autor:
Elena Garralda, Marc Oliva, Irene Brana, Robin M. Hallett, Joan Seoane, Enda Moran, Dorotea Maetzel, Maria Vieito Villar, Patricia Giblin, Nehal Lakhani, Alison M. Schram, Josep Tabernero, Anna Spreafico, Lillian L. Siu, Daniel D. Von Hoff, Kimberly Hoffmann, Robert Wasserman, Judit Anido, Erkut Borazanci, Adrianne Kelly
Publikováno v:
Cancer Research. 80:CT147-CT147
Leukemia Inhibitory Factor (LIF) is a pleiotropic cytokine, which is highly expressed in a subset of tumors and correlates with poor prognosis. LIF is hypothesized to contribute to tumor microenvironment immunosuppression and regulation of cancer ste
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::88ec6a1bb1963c37efdf25288bbf59ce
https://doi.org/10.1158/1538-7445.am2020-ct147
https://doi.org/10.1158/1538-7445.am2020-ct147
Autor:
Tatiana Hernandez-Guerrero, Juan De Alvaro, Manisha Lamba, Ellen Filvaroff, Olga Ferrero, Marina Arias, Juan Manuel Manuel Sepulveda Sanchez, Marlene Zuraek, Zariana Nikolova, Victor Moreno, Tania Sánchez Pérez, Irene Brana, Rafael Sarmiento, Bernard Doger, Bishoy Hanna, O. Saavedra, Ida Aronchik, Maria Vieito Villar, Jorge DiMartino
Publikováno v:
Journal of Clinical Oncology. 37:3015-3015
3015 Background: Bromodomain and extra-terminal (BET) proteins are epigenetic readers that control expression of genes involved in cell growth and oncogenesis. CC-90010 is an oral, potent and reversible BET inhibitor that showed promising activity in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aa718a45aa431f92c5b76a3020c1389e
https://doi.org/10.1200/jco.2019.37.15_suppl.3015
https://doi.org/10.1200/jco.2019.37.15_suppl.3015
Autor:
Cinta Hierro, Maria Vieito Villar, Guillem Argiles, Cristina Viaplana, Juan Martin-Liberal, O. Saavedra, Helena Verdaguer, Analia Azaro, Josep Tabernero, Mafalda Oliveira, Ignacio Matos, Eva Muñoz-Couselo, Elena Garralda, I. Gardeazabal, Maria Ochoa de Olza, Alejandro Navarro, Rodrigo Dienstmann, Joan Carles, Guillermo Villacampa, Irene Brana
Publikováno v:
Journal of Clinical Oncology. 37:2580-2580
2580 Background: There have been important changes in early drug development units with an unprecedented increase of immune-oncology (IO) trials. Currently at the Vall d’Hebron Institute Oncology (VHIO) close to 50% of our Phase 1 trials (Ph1t) por
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::91dd531a56da9566be4d54d88125ff7a
https://doi.org/10.1200/jco.2019.37.15_suppl.2580
https://doi.org/10.1200/jco.2019.37.15_suppl.2580
Autor:
M. Caeiro, Martin Lázaro Quintela, Carolina Pena, Elena Brozos, Jl Firvida, Clara Senin Estor, Silvia Varela Ferreiro, G. Huidobro, J.E. Castro, M.J. Villanueva, Maria Vieito Villar, Pilar M. Calvo, Urbano Anido, MB Taboada, Joaquin Casal Rubio, E. Hernandez, Sergio Vazquez-Estevez, Nieves Martinez, MC Areses
Publikováno v:
Journal of Clinical Oncology. 31:7549-7549
7549 Background: CChRT is recommended as the evidence-based approach for the management of patients (p) with locally advanced stage III NSCLC and a good performance status, although a clearly superior regimen has not been identified. The aim of our s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d0a4b387e2c7945872f67999fbdab31c
https://doi.org/10.1200/jco.2013.31.15_suppl.7549
https://doi.org/10.1200/jco.2013.31.15_suppl.7549